Liquid oral composition and liquid relaxant

Abstract

To provide a liquid oral composition and a liquid relaxant that enable relaxation through a sensation of use that suppresses physiological arousal.SOLUTION: The liquid oral composition and the liquid relaxant contain 0.2 mass% or more of an anionic surfactant, have a viscosity of 20 mPa s or more and 65 mPa s or less at 30°C and a shear rate of 8 s-1, and have a viscosity of 10 mPa s or more and 30 mPa s or less at 30°C and a shear rate of 76 s-1.SELECTED DRAWING: Figure 2

Description

[Technical Field]

[0001] The present invention relates to a liquid oral composition and a liquid relaxant. [Background technology]

[0002] Anionic surfactants are generally used in liquid oral compositions, which have the effect of efficiently removing dirt and bacteria from the oral cavity by increasing the solubility of oil-soluble components.

[0003] Patent Document 1 describes an invention related to a liquid oral composition. The liquid oral composition described therein contains a specific carbonate, an anionic surfactant, and a polyvalent metal cation in the presence of a specific amount of water, and is adjusted to a specific alkaline pH range. The content of the anionic surfactant is 0.2% by mass or more to effectively enhance the stain removal effect. Furthermore, the content is 1.7% by mass or less to effectively suppress harmful effects on the gums and oral mucosa and maintain a good flavor. This results in a liquid oral composition that is excellent in stain removal effect and maintains a good feel when used. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2017 / 104664 Summary of the Invention [Problem to be solved by the invention]

[0005] However, when the amount of anionic surfactants blended is large, it can cause mucosal irritation accompanied by a tingling sensation. Such mucosal irritation is thought to lead to physiological arousal, and may not be suitable for use in situations where physiological sedation is desired, such as before going to bed. There is a demand for a feel that reduces the irritation caused by anionic surfactants and suppresses physiological arousal.

[0006] The present invention has been made in consideration of these circumstances, and its object is to provide a liquid oral composition and a liquid relaxant that have a relaxing effect. [Means for solving the problem]

[0007] The liquid oral composition for solving the above problems contains 0.2% by mass or more of an anionic surfactant, and is sintered at 30°C and a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 The viscosity is 10 mPa·s or more and 30 mPa·s or less.

[0008] The liquid relaxant for solving the above problems contains 0.2% by mass or more of an anionic surfactant and is soluble in water at 30°C and a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 The viscosity is 10 mPa·s or more and 30 MmPa·s or less.

[0009] According to the above-mentioned configuration, the liquid oral composition and the liquid relaxant are given a unique viscosity. Because the mouthfeel is smooth, irritation to the oral mucosa is reduced even when an anionic surfactant is blended. Physiological arousal is suppressed, resulting in a relaxing effect. [Effects of the Invention]

[0010] According to the present invention, a relaxing effect can be obtained by using the product with a feeling of suppression of physiological arousal. [Brief explanation of the drawings]

[0011] [Figure 1] This shows the change in parasympathetic nervous index over time when rinsing the mouth with liquid oral compositions of the examples and comparative examples. [Figure 2]This figure shows the average interval of the increase in parasympathetic nervous index during the recovery period after a stressful task when rinsing with the liquid oral compositions of the examples and comparative examples. DETAILED DESCRIPTION OF THE INVENTION

[0012] Hereinafter, one embodiment of the liquid oral composition and liquid relaxant of the present invention will be described. Hereinafter, the liquid oral composition and liquid relaxant may be simply referred to as the oral composition.

[0013] The oral composition of the present embodiment contains an anionic surfactant. The anionic surfactant is not particularly limited, and conventionally known anionic surfactants can be used.Specific examples thereof include alkyl sulfates, alkyl sulfate ester salts, alkyl ether sulfates, alkyl ether sulfate ester salts, alkyl sulfosuccinates, alkyl ether sulfosuccinates, acyltaurine salts, acylamino acid salts, alkyl ether carboxylates, alkyl phosphates, alkyl ether phosphates, fatty acid monoglyceride sulfates, alkyl sulfoacetates, etc.

[0014] Among these, alkyl sulfates, alkyl ether sulfates, alkyl sulfosuccinates, acylamino acid salts, and alkyl phosphates are preferred. These anionic surfactants are preferred because they have excellent water solubility, good compatibility with other ingredients, and low irritation.

[0015] The anionic surfactants may be used alone or in combination of two or more. Specific examples of alkyl sulfates include sodium lauryl sulfate and sodium myristyl sulfate. Specific examples of alkyl ether sulfates include polyoxyethylene alkyl ether sulfates. Specific examples of alkyl sulfosuccinates include polyoxyethylene alkyl sulfosuccinates. Specific examples of acylamino acid salts include acyl sarcosine salts such as lauroyl sarcosine salt and myristoyl sarcosine salt, acyl glutamates such as lauroyl glutamate, myristoyl glutamate, palmitoyl glutamate and cocoyl glutamate, acyl glycine salts such as N-lauroyl-N-methyl glycine salt and cocoyl glycine salt, acyl alanine salts such as N-lauroyl-β-alanine salt, N-myristyl-β-alanine salt, N-cocoyl-β-alanine salt, N-lauroyl-N-methyl-β-alanine salt, N-myristoyl-N-methyl-β-alanine salt and N-methyl-N-acylalanine salt, and acyl aspartates such as lauroyl aspartate. Specific examples of alkyl phosphates include lauryl phosphate, etc.

[0016] The anionic surfactant is contained in the oral composition at 0.2% by mass or more. A content of the anionic surfactant of 0.2% by mass or more improves the solubility of oil-soluble components in the oral cavity, allowing for efficient removal of dirt and bacteria adhering to the oral cavity. Furthermore, the anionic surfactant is preferably contained in the oral composition at 2.0% by mass or less, more preferably 1.5% by mass or less. By keeping the content of the anionic surfactant within this range, excessive irritation in the oral cavity is suppressed. The content of each component in the oral composition refers to the content in the oral composition including a solvent such as water.

[0017] The viscosity of the oral composition was 30°C and a shear rate of 8 s. -1 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1The viscosity of the oral composition is 10 mPa·s or more and 30 mPa·s or less. When the viscosity of the oral composition is in this range, the oral composition is given an appropriate thickness. When the oral composition is placed in the mouth, the mouthfeel is smooth and mucosal irritation is reduced.

[0018] The oral composition contains a viscosity modifier to adjust the viscosity within the above range. The viscosity modifier is not particularly limited, and conventionally known viscosity modifiers can be used. Specific examples of viscosity modifiers include cellulose derivatives such as sodium carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose; alkali metal alginates such as sodium alginate; propylene glycol alginate; gums such as xanthan gum, gellan gum, locust bean gum, tragacanth gum, karaya gum, gum arabic, carrageenan, guar gum, and tara gum; and synthetic binders such as polyvinyl alcohol, sodium polyacrylate, carboxyvinyl polymer, and polyvinylpyrrolidone. For example, xanthan gum has good solubility in water and excellent stability over a wide temperature and pH range. It is also preferred because it can impart an appropriate thickness at a low concentration. The viscosity modifiers may be used alone or in combination of two or more.

[0019] The content of the viscosity adjuster in the oral composition can be adjusted appropriately depending on the viscosity adjuster used. The oral composition may contain other ingredients besides the anionic surfactant and viscosity adjuster, such as antibacterial agents, anti-inflammatory agents, fragrances, humectants, surfactants other than anionic surfactants, alcohols, sweeteners, medicinal ingredients, colorants, stabilizers, pH adjusters, etc., depending on the intended application, form, and use. These ingredients may be any of those conventionally known to be contained in oral compositions. These ingredients may be used singly or in combination of two or more.

[0020] Specific examples of antibacterial agents include cetylpyridinium chloride, paraben, sodium benzoate, triclosan, chlorhexidine hydrochloride, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride, and hinokitiol.

[0021] Specific examples of anti-inflammatory agents include glycyrrhizinate, tranexamic acid, ε-aminocaproic acid, and Phellodendron Bark extract. Specific examples of fragrances include anethole, eugenol, carvone, wintergreen, methyl salicylate, thymol, clove oil, sage oil, ocimene oil, and citronellol.

[0022] Specific examples of the humectant include polyhydric alcohols such as sorbitol, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, and polyethylene glycol.

[0023] Specific examples of surfactants other than anionic surfactants include nonionic surfactants and amphoteric surfactants. Specific examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters and maltose fatty acid esters, sugar alcohol fatty acid esters such as maltitol fatty acid esters, sorbitan fatty acid esters such as sorbitan monolaurate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate and polyoxyethylene sorbitan monostearate, fatty acid alkanolamides such as lauric acid diethanolamide, polyoxyethylene alkyl ethers such as polyoxyethylene stearyl ether and polyoxyethylene oleyl ether, polyethylene glycol fatty acid esters such as polyethylene glycol monooleate and polyethylene glycol monolaurate, alkyl glucosides such as lauryl glucoside and decyl glucoside, polyglycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene hydrogenated castor oil, glycerin fatty acid esters, and polyoxyethylene propylene block copolymers.

[0024] Specific examples of amphoteric surfactants include amino acid-type amphoteric surfactants such as N-lauryldiaminoethylglycine and N-myristyldiethylglycine, and betaine-type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine, N-alkyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine salt, and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine.

[0025] Specific examples of alcohols include ethyl alcohol, lauryl alcohol, and myristyl alcohol. Specific examples of sweetening ingredients include saccharin, saccharin sodium, sucralose, stevioside, acesulfame potassium, aspartame, xylitol, maltitol, erythritol, and cycloheptaamylose.

[0026] Specific examples of medicinal ingredients include fluorides such as sodium monofluorophosphate, sodium fluoride, stannous fluoride, and strontium fluoride; condensed phosphates such as sodium pyrophosphate and sodium polyphosphate; phosphates such as sodium monohydrogen phosphate and trisodium phosphate; vitamins such as ascorbic acid, sodium ascorbate, pyridoxine hydrochloride, and tocopherol acetate; glucanase enzymes such as dextranase and mutanase; proteases; degradative enzymes such as lysozyme; inorganic salts such as zinc chloride, zinc citrate, strontium chloride, and potassium nitrate; chelating compounds such as chlorophyll and glycerophosphate; fat-dissolving polyethylene glycol; sodium chloride, aluminum lactate, and strontium chloride.

[0027] Specific examples of colorants include legally designated dyes such as Green No. 1, Blue No. 1, and Yellow No. 4, and titanium oxide. Specific examples of stabilizers include sodium edetate, sodium thiosulfate, sodium sulfite, calcium lactate, lanolin, triacetin, castor oil, magnesium sulfate, and the like.

[0028] Specific examples of pH adjusters include citric acid, malic acid, lactic acid, tartaric acid, acetic acid, phosphoric acid, pyrophosphoric acid, glycerophosphoric acid, and various salts thereof such as potassium salts, sodium salts, and ammonium salts, as well as sodium hydroxide, etc. The oral composition is preferably adjusted to a pH of 4 to 9, particularly 5 to 7, by incorporating a pH adjuster. Having the pH of the oral composition within this range reduces irritation in the oral cavity and improves usability.

[0029] From the viewpoint of application to the oral cavity, the solvent used in the oral cavity composition is preferably, for example, water, ethanol, or a mixture thereof. As water, purified water, ionized water, distilled water, pure water, ultrapure water, tap water, etc. can be used. The content of the solvent is preferably 60 to 99.8% by mass, more preferably 70 to 90% by mass.

[0030] The application form of the oral composition is not particularly limited, and it can be used, for example, as a pharmaceutical or quasi-drug. Oral compositions are liquid compositions intended primarily for use in the oral cavity. The uses of oral compositions are not particularly limited, but they can be used, for example, as a mouthwash by placing an appropriate amount in the oral cavity and rinsing. They can also be used as liquid dentifrices, including those containing abrasives such as calcium hydrogen phosphate, aluminum hydroxide, anhydrous silicic acid, and calcium carbonate as needed. They can also be used as a spray to be sprayed into the oral cavity as a mouth freshener. They can also be used as a mouthwash. Other uses include, for example, a breath freshener, a gum massage agent, an oral moisturizer, a tongue coating remover, an oral lining agent, an oral disinfectant, a throat disinfectant, an oral throat remedy, a periodontal disease treatment agent, a denture coating agent, a denture cleaner, and an implant care agent.

[0031] According to this embodiment, the following effects can be obtained. (1) The oral composition of this embodiment contains 0.2% by mass or more of an anionic surfactant and is soluble in water at 30°C and a shear rate of 8 s -1The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 The viscosity is between 10 mPa·s and 30 mPa·s. This viscosity range gives oral compositions their characteristic thick consistency. It has a smooth mouthfeel and is less likely to irritate the oral mucosa, even though it contains an anionic surfactant. This suppresses physiological arousal and provides a relaxing effect.

[0032] (2) The anionic surfactant is at least one selected from alkyl sulfates, alkyl ether sulfates, alkyl sulfosuccinates, acylamino acid salts, and alkyl phosphates. These anionic surfactants are highly water-soluble, have good compatibility with other ingredients, and are low-irritation. Therefore, an oral composition having good cleansing properties and an excellent relaxing effect can be obtained.

[0033] (3) The liquid relaxant of this embodiment contains 0.2% by mass or more of an anionic surfactant and is soluble in water at 30°C and a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 The viscosity is 10 mPa·s or more and 30 mPa·s or less. Therefore, the same effect as in (1) above can be obtained.

[0034] The above embodiment can be modified as follows: The above embodiment and the following modifications can be combined and applied within the scope of technical compatibility.

[0035] The oral composition of the above embodiment is used at 30°C and a shear rate of 8 s -1 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 The viscosity may be adjusted to 10 mPa·s or more and 30 mPa·s or less at 200°C. This can be achieved by blending a predetermined amount of the viscosity adjuster described above at the time of use, for example, to obtain an oral composition having the predetermined viscosity.

[0036] Alternatively, the oral composition containing the viscosity adjuster may be stored as a solid such as a powder, and then adjusted to a liquid form by adding a solvent such as water when used. Even in this configuration, by adjusting the viscosity to a specific level, mucosal irritation in the oral cavity can be suppressed, thereby achieving a relaxing effect.

[0037] The technical concepts understood from the above embodiment will be described below. (A) A viscosity modifier and an anionic surfactant in an amount of 0.2% by mass or more are contained, and the viscosity is measured at 30°C and a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 A liquid oral composition characterized by having a viscosity of 10 mPa·s or more and 30 mPa·s or less.

[0038] (b) The liquid oral composition described in (a), characterized in that the viscosity adjuster is at least one selected from alkali metal alginate, xanthan gum, gellan gum, locust bean gum, tragacanth gum, karaya gum, gum arabic, carrageenan, and guar gum.

[0039] (c) A composition containing a viscosity modifier and 0.2% by mass or more of an anionic surfactant, and having a viscosity of 30°C and a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 A liquid relaxant characterized by having a viscosity of 10 mPa·s or more and 30 mPa·s or less. [Example]

[0040] The liquid oral composition of the present invention will be described in more detail based on the following examples. Note that the present invention is not limited to the configurations described in the examples. (Preparation of oral composition) Oral compositions of Examples 1 and 2 and Comparative Examples 1 and 2 shown in Table 1 were prepared. Each oral composition was prepared by mixing and stirring the components according to a conventional method. In Table 1, the numerical value written to the right of each component indicates the content (% by mass) of each component in the oral composition.

[0041] As an anionic surfactant, 0.2% by mass of sodium lauryl sulfate was blended. As a viscosity modifier, 0.32% by mass of sodium alginate was blended in Example 1, and 0.16% by mass of sodium alginate was blended in Comparative Example. In Example 2, 0.08% by mass of xanthan gum was blended. In Comparative Example 2, no viscosity modifier was blended.

[0042] (Evaluation test) The viscosity of the oral compositions of Examples 1 and 2 and Comparative Examples 1 and 2 was measured, and the relaxing effect, irritation, and discomfort after spitting were evaluated when each oral composition was used. The relaxing effect was evaluated based on the physiological sedative effect.

[0043] (viscosity measurement) A cone-plate viscometer LVDV-II+PRO (manufactured by Brookfield) was used to measure the viscosity of each oral composition of Examples 1 and 2 and Comparative Examples 1 and 2. Each oral composition was poured into a measuring cup, and the measuring part was kept at 30°C. The shear rate was 8 s -1 If set to , 76s -1 Measurements were started under both conditions. The viscosity at each shear rate is shown in Table 1.

[0044] (Evaluation of physiological sedative effect) The physiological sedative effect was evaluated by performing a short-term stressful calculation task, and then assessing recovery from the stress state using autonomic nervous system indices. Evaluation of autonomic nervous system indices was performed by measuring the high-frequency component (HF) (range: 0.15-0.40 Hz) obtained from heart rate variability data, which is an index of cardiac parasympathetic nervous activity. Heart rate variability data represents an index of change in the time interval between successive heartbeats, and the high-frequency component (HF) of heart rate variability data is related to cardiac parasympathetic nervous activity.

[0045] For the evaluation of physiological sedative effects, 21 subjects, 11 healthy adult males and 10 healthy adult females, were used as subjects. After a 10-minute rest period, each subject performed the Kraepelin test, a stressful calculation task, continuously for 20 minutes. Then, 10 ml of the oral composition prepared in each Example and Comparative Example was placed in the mouth as a mouthwash and rinsed for 20 seconds. After spitting out the mouthwash, the subjects rested for 20 minutes to recover from the stress.

[0046] Each subject wore an electrocardiogram sensor to measure heart rate variability data during the resting, stressful, and recovery periods. Heart rate variability data was measured using a BioAmp MP150 (BIOPAC Systems Inc.).

[0047] A within-subjects design was used, and the order of sample presentation was random. (Evaluation criteria for physiological sedative effect) The evaluation criterion for physiological sedation effect was the z-score, which was obtained by standardizing and converting the HF value obtained from the heart rate variability data in measuring physiological sedation effect.

[0048] The z-score was calculated using the following formula: Z=(X-μ) / σ Here, X is the sample data, μ is the mean of X, and σ is the standard deviation.

[0049] The z-score, which is the normalized HF value, decreases during the stressful task and then gradually increases. The results of the changes in z-score for the oral compositions of Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Figure 1. Furthermore, the z-score at the end of the stressful task, indicated by the thick horizontal line in Figure 1, was used as the base line, and the average interval of the changes in z-score (increase) for 20 minutes after the task (recovery period) was calculated for 21 subjects. The results are shown in Figure 2.

[0050] The physiological sedative effect was evaluated from the calculated average values ​​based on the following evaluation criteria. The results are shown in the "Physiological sedative effect" column in Table 1. ◎: z is 0.8 or more 〇: z is less than 0.8, 0.65 or more △: z is less than 0.65, 0.5 or more ×: z is less than 0.5 (Evaluation of irritation and discomfort after vomiting) The evaluation of irritation and post-spitting discomfort was conducted by four expert panelists. Each subject held 10 ml of the oral composition prepared in each Example and Comparative Example in their mouth as a mouthwash and rinsed their mouth for 20 seconds. After spitting out the mouthwash, the subject evaluated the irritation and post-spitting discomfort.

[0051] (Evaluation criteria for irritation and discomfort after vomiting) The irritating sensation and discomfort after vomiting were scored based on the following evaluation criteria. The scores were the same for both the irritating sensation and the discomfort after vomiting.

[0052] 5: Irritation / strong discomfort after vomiting 4: Irritation / discomfort after vomiting 3: Irritation / slight discomfort after vomiting 2: Slight irritation / discomfort after vomiting 1: No irritation / discomfort after vomiting Based on these scores, the average scores of the four panelists were evaluated according to the following criteria.

[0053] ◎: Less than 2 points ○: 2 points or more but less than 3 points △: 3 points or more but less than 4 points ×: 4 points or more The evaluation results of the irritation sensation and discomfort after vomiting are shown in the "irritation sensation" and "discomfort when vomiting" columns of Table 1.

[0054] [Table 1] As shown in Figure 1, the HF value decreased due to the short-term stress load of the calculation task, and an acute stress response was observed. On the other hand, a temporary increase in the HF value was observed upon the end of the short-term stress load. After that, when the oral compositions of Examples 1 and 2 were used for mouth rinsing, the increased HF value remained at a high level, whereas when the oral compositions of Comparative Examples 1 and 2 were used for mouth rinsing, the increase in the HF value during the recovery period was small.

[0055] This point was also clear from the results of calculating the interval average of the change in z value during the recovery period. As shown in Figure 2, the interval average of the increase in HF value during the recovery period was significantly higher for the oral compositions of Examples 1 and 2, which had a predetermined viscosity (thickness), than for the oral compositions of Comparative Examples 1 and 2. It was found that recovery from stress was faster and greater.

[0056] Furthermore, the results of the sensory evaluation showed that when rinsing the mouth with the oral compositions of Examples 1 and 2, there was little irritation or discomfort after spitting out, whereas when rinsing the mouth with the oral compositions of Comparative Examples 1 and 2, there was a strong irritation.

[0057] These results are obtained at a shear rate of 8 s -1 The viscosity is 20 mPa·s or more and 65 mPa·s or less at 30°C and a shear rate of 76 s -1 These results suggest that oral compositions with a viscosity of 10 mPa·s or more and 30 mPa·s or less effectively promote recovery from physiological stress responses and are suitable for relaxation effects.

[0058] (Prescription example) Formulation Examples 1 to 4 of the liquid oral composition of the present invention are shown in Table 2 below. The numbers written to the right of each component indicate the content (mass%) of each component in each oral composition. The same effects as those of the above examples were confirmed for each formulation example.

[0059] [Table 2]

Claims

1. Contains 0.2% by mass or more of an anionic surfactant, 30°C, shear rate 8 s －１ The viscosity at 30°C and a shear rate of 76 s is 20 mPa·s or more and 65 mPa·s or less. －１ A liquid oral composition characterized by having a viscosity of 10 mPa・s or more and 30 mPa・s or less.

2. The liquid oral composition as described in claim 1, wherein the anionic surfactant is at least one selected from alkyl sulfates, alkyl ether sulfates, alkyl sulfosuccinates, acylamino acid salts, and alkyl phosphates.

3. Contains 0.2% by mass or more of an anionic surfactant, 30°C, shear rate 8 s －１ The viscosity at 30°C and a shear rate of 76 s is 20 mPa·s or more and 65 mPa·s or less. －１ A liquid relaxant characterized by having a viscosity of 10 mPa·s or more and 30 mPa·s or less.

Images